# Masteron Propionate

*Also known as: Drostanolone Prop, Mast P*

DHT-derived drostanolone propionate; anti-estrogenic, cutting agent. Simple model — peak calibrated.

## Overview

Masteron (drostanolone propionate) is an injectable DHT derivative carrying a C17beta propionate ester, originally developed clinically (as Drolban) for breast cancer before being displaced by tamoxifen. It binds the androgen receptor, does not aromatize, and is not further 5-alpha-reduced, which is why it earned a reputation as an anti-estrogenic cutting agent (it competes weakly at the aromatase and estrogen receptor level). Its 2-day half-life (48 hours) requires every-other-day injection to keep serum levels flat in research protocols. Hepatotoxicity is rated none, the side-effect profile is comparatively mild, and the primary harm-reduction concerns are androgenic (hair, skin, prostate in susceptible users) plus HPTA suppression, which is dose- and duration-dependent. Because it is a pure DHT derivative with no estrogenic conversion, it is typically stacked rather than run alone.

## Pharmacokinetics

- **Model tier:** simple
- **Half-life:** 2.0 days (48 hours)
- **Cmax:** 71.3 ng/dL
- **Bioavailability:** 84%

## Dosing

- **Default dose:** 100 mg
- **Typical range:** 50–150 mg
- **Units:** ng/dL

## Harm reduction

- **Aromatizes:** No
- **DHT derivative:** Yes
- **Injection frequency:** EOD

## Source

- **Label:** Wikipedia (Llewellyn 2011)
- **URL:** https://en.wikipedia.org/wiki/Drostanolone_propionate
- **Notes:** Cmax calibrated to ng/dL serum peak.

---

**Canonical URL:** https://anabolicdex.com/compounds/masteron-propionate
**Plot:** https://anabolicdex.com/plot?compound=masteron-propionate